Treatment adherence
Real-world tofersen lowers neurofilaments in SOD1-ALS
Metadata + PaperFren explanation · cc by · source: Europe PMC
In 24 German early-access SOD1-ALS patients, tofersen slowed ALSFRS-R decline versus pre-treatment and cut serum NfL and CSF pNfH, but CSF pleocytosis was common.
Study at a glance
- Design
- Other — Prospective observational follow-up in Germany’s tofersen early-access program across ten MND-NET centres
- N
- N=24 · SOD1-ALS patients treated March 2022–April 2023
- Population
- Adults with SOD1-ALS in a German early-access programme
- Outcome
- ALSFRS-R progression and serum/CSF neurofilament change on tofersen
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
Median ALSFRS-R decreased from 38.0 to 35.0 (progression 0.11 points/month), slower than pre-baseline progression (0.41 points/month; p = 0.04 in subset). Serum NfL and CSF pNfH each fell significantly (p = 0.02). No deaths occurred, but pleocytosis appeared in 73% and intrathecal immunoglobulin synthesis in 90%; two drug-related serious adverse events included autoimmune myeloradiculitis requiring immunotherapy.
Methodology
Investigators followed 24 SOD1-ALS patients treated via Germany’s tofersen early access program (March 2022–April 2023) across ten MND-NET centers. They tracked ALSFRS-R, progression rate, quality of life, serum NfL, CSF pNfH, CSF inflammatory markers, and adverse events using a uniform protocol and central CSF/blood assays.
Limitations
There was no placebo control, sample size was small, follow-up was short and heterogeneous, and pre-baseline slopes relied on recall—so clinical benefit beyond biomarker change remains uncertain and placebo effects cannot be excluded.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Higher plasma NfL associates with higher later dementia risk in UK Biobank adults.
In UK Biobank adults with baseline plasma measures, higher NfL (and GFAP) associated with roughly doubled hazards of incident all-cause dementia over ~13 years, with protein elevations detectable up to about 15 years before diagnosis and useful incremental prediction alongside demographic risk scores.
Scope note — different disease context — SOD1-ALS pharmacodynamics, not dementia prognosis
Limits the claim's scope: a different population, assay, or outcome.
In SOD1-ALS care, treatment can lower serum NfL as injury markers fall.
In German early-access SOD1-ALS care, tofersen treatment was accompanied by significant falls in serum NfL and CSF pNfH, with ALSFRS-R progression slower than patients’ pre-treatment slopes in the analyzed subset.
Evidence for the claim as stated.
UK Biobank treats baseline plasma NfL as a long-horizon prognostic marker for dementia in a general volunteer cohort. The tofersen series treats serial NfL/pNfH as a pharmacodynamic injury marker in SOD1-ALS. Both can be valid for their questions—the limit is not picking a winner, but not swapping prognostic and treatment-monitoring readings.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
UK Biobank treats baseline plasma NfL as a long-horizon prognostic marker for dementia in a general volunteer cohort. The tofersen series treats serial NfL/pNfH as a pharmacodynamic injury marker in SOD1-ALS. Both can be valid for their questions—the limit is not picking a winner, but not swapping prognostic and treatment-monitoring readings.
Related papers in this topic
Same topic cluster — not a recommendation engine.